WAYNE, PA — Teleflex Incorporated (NYSE: TFX) announced this week new research findings that highlight the benefits of the Prostatic Urethral Lift (PUL) using the UroLift™ System for benign prostatic hyperplasia (BPH)—a condition causing enlargement of the prostate gland. This marks the first time outcomes from two head-to-head trials have been presented, depicting UroLift™ as a leading minimally invasive surgical therapy known for quick symptom relief and enduring outcomes while preserving sexual function.
The new research and real-world studies confirm the UroLift™ System’s unique benefits in patient experience, making it a front-runner as an early treatment option for men experiencing life-altering BPH symptoms. Jacqueline Welch, Vice President of Global Clinical and Scientific Operations at Teleflex, emphasized the company’s decade-long commitment to advancing BPH research through various trials involving the UroLift™ system and other modern treatments.
The research presentations unraveled key findings from the studies. The most expansive randomized controlled trial (RCT) thus far compared early patient outcomes between UroLift™ PUL and Tamsulosin medication. Initial data lean towards the UroLift™ system, providing better symptom relief and improvements in the quality of life and patient satisfaction three months post-treatment initiation.
Another head-to-head study showcased the superior early patient experience with the UroLift™ System against Rezūm’s water vapor thermal therapy (WVTT). In this case, patients using UroLift™ also experienced quicker symptom relief and improvements in quality of life within three months post-treatment.
Interestingly, a broad analysis of post-surgery medication usage over five years found similar usage rates among patients treated with the UroLift™ System, transurethral resection of the prostate (TURP), and GreenLight™ photoselective vaporization (PVP). The similarity in medication use may suggest that not all TURP and PVP patients fully reap the benefits of the intervention, contrary to what one might expect in a real-world setting.
In terms of unplanned post-surgical visits, UroLift™ PUL came ahead with the lowest hospitalizations and emergency department visits. In another review of the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database, UroLift™ PUL had the lowest rates of mild, moderate, and severe complications year over year, once the procedure volume is accounted for.
Claus Roehrborn, MD, professor of urology at UT Southwestern Medical Center, and primary investigator on the study, acknowledged that the initial results offer a better understanding of efficacy comparisons, patient satisfaction, and goal attainment, with UroLift™ emerging as advantageous.
Teleflex also showcased the recently FDA-approved UroLift™ 2 System with Advanced Tissue Control (ATC). The upgrade is designed to offer physicians enhanced confidence, improved control of obstructive tissue, and targeting accuracy.
BPH is a common issue as men age, potentially causing bothersome urinary symptoms due to the urethra’s obstruction. The UroLift™ System shines as a minimally invasive BPH treatment option, helping men to discontinue BPH medications, avoid major surgery, and preserve sexual function. It’s unique as a leading enlarged prostate procedure that doesn’t require heating, cutting, or destruction of prostate tissue, thus making it a noteworthy advancement in men’s health.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.